Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Personal Author:
St. Cyr, Sancta ; Barbee, Lindley ; Workowski, Kimberly A. ; Bachmann, Laura H. ; Pham, Cau ; ... More +
St. Cyr, Sancta ; Barbee, Lindley ; Workowski, Kimberly A. ; Bachmann, Laura H. ; Pham, Cau ; Schlanger, Karen ; Torrone, Elizabeth ; Weinstock, Hillard ; Kersh, Ellen N. ; Thorpe, Phoebe Less -
Description:
Sexually transmitted infections (STIs) caused by the bacteria Neisseria gonorrhoeae (gonococcal infections) have increased 63% since 2014 and are a cause of sequelae including pelvic inflammatory disease, ectopic pregnancy, and infertility and can facilitate Transmission of human immunodeficiency Virus (HIV) (1,2). Effective treatment can prevent Complications and Transmission, but N. gonorrhoeae's ability to acquire antimicrobial resistance influences treatment recommendations and complicates control (3). In 2010, CDC recommended a single 250 mg intramuscular (IM) dose of ceftriaxone and a single 1 g oral dose of azithromycin for treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum as a strategy for preventing ceftriaxone resistance and treating possible coinfection with Chlamydia trachomatis (4). Increasing concern for antimicrobial stewardship and the potential impact of dual therapy on commensal organisms and concurrent pathogens (3), in conjunction with the continued low incidence of ceftriaxone resistance and the increased incidence of azithromycin resistance, has led to reevaluation of this recommendation. This report, which updates previous guidelines (5), recommends a single 500 mg IM dose of ceftriaxone for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea. If chlamydial infection has not been excluded, concurrent treatment with doxycycline (100 mg orally twice a day for 7 days) is recommended. Continuing to monitor for emergence of ceftriaxone resistance through Surveillance and health care providers' reporting of treatment failures is essential to ensuring continued efficacy of recommended regimens.
Subjects:
[+]
Administration, Oral Ceftriaxone Chlamydia Infections Chlamydia Trachomatis Coinfection Doxycycline Evidence-Based Medicine Full Report Gonorrhea Humans Injections, Intramuscular Practice Guidelines As Topic
Source:
MMWR Morb Mortal Wkly Rep. 69(50):1911-1916
Pubmed ID:
33332296
Pubmed Central ID:
PMC7745960
Document Type:
Journal Article
Name as Subject:
Centers for Disease Control and Prevention (U.S.) ; Centers for Disease Control and Prevention (U.S.)
Centers for Disease Control and Prevention (U.S.) ; Centers for Disease Control and Prevention (U.S.) Less -
Place as Subject:
United States
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:1406f24b4e8047f39f0c2acfe8e9c532f31a93605764601b49355bdfcbfbbd43
Download URL:
https://stacks.cdc.gov/view/cdc/100101/cdc_100101_DS1.pdf
File Type:

Supporting Files

• 	mm6950a6-F.gif	gif
  	mm6950a6-F.jpg	jpeg
  	mm6950a6.nxml	xml

More +